amybunny personal page - To The Moon

amybunny

amybunny

No personal profile

9Follow

1Followers

0Topic

0Badge

2022-11-07

$Coca-Cola(KO)$[Cool]

2022-10-25

$Straits Times Index(STI.SI)$good to buy?

2022-01-29

Unit confident to buy any of this stock

Hot Chinese ADRs Dropped in Morning Trading

2022-01-29

$Nu Holdings Ltd.(NU)$Should buy more share to lower the average cost or just leave itas it? What's your plan?

2022-01-05

Sit tight

Is Now a Good Time to Buy Moderna Stock?

2021-12-31

Good

Toplines Before US Market Open on Thursday

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4101690391425510","uuid":"4101690391425510","gmtCreate":1638593463869,"gmtModify":1638678289015,"name":"amybunny","pinyin":"amybunny","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/eff2c98f1ea4d96950f8559f25c1c8f0","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":9,"tweetSize":9,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.08.31","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":9987012142,"gmtCreate":1667778603486,"gmtModify":1676537960702,"author":{"id":"4101690391425510","authorId":"4101690391425510","name":"amybunny","avatar":"https://static.tigerbbs.com/eff2c98f1ea4d96950f8559f25c1c8f0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4101690391425510","authorIdStr":"4101690391425510"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/KO\">$Coca-Cola(KO)$</a>[Cool]&nbsp;","listText":"<a href=\"https://ttm.financial/S/KO\">$Coca-Cola(KO)$</a>[Cool]&nbsp;","text":"$Coca-Cola(KO)$[Cool]","images":[{"img":"https://community-static.tradeup.com/news/277225a60cc4e78705823b6c7965fc4c","width":"1179","height":"2316"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9987012142","isVote":1,"tweetType":1,"viewCount":209,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9988313961,"gmtCreate":1666664985053,"gmtModify":1676537786147,"author":{"id":"4101690391425510","authorId":"4101690391425510","name":"amybunny","avatar":"https://static.tigerbbs.com/eff2c98f1ea4d96950f8559f25c1c8f0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4101690391425510","authorIdStr":"4101690391425510"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/STI.SI\">$Straits Times Index(STI.SI)$</a>good to buy?","listText":"<a href=\"https://ttm.financial/S/STI.SI\">$Straits Times Index(STI.SI)$</a>good to buy?","text":"$Straits Times Index(STI.SI)$good to buy?","images":[{"img":"https://community-static.tradeup.com/news/113b2a06bb22ab09d533f5a466b895ba","width":"1125","height":"1744"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9988313961","isVote":1,"tweetType":1,"viewCount":246,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9099475962,"gmtCreate":1643419570470,"gmtModify":1676533818623,"author":{"id":"4101690391425510","authorId":"4101690391425510","name":"amybunny","avatar":"https://static.tigerbbs.com/eff2c98f1ea4d96950f8559f25c1c8f0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4101690391425510","authorIdStr":"4101690391425510"},"themes":[],"htmlText":"Unit confident to buy any of this stock&nbsp;","listText":"Unit confident to buy any of this stock&nbsp;","text":"Unit confident to buy any of this stock","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9099475962","repostId":"1144860170","repostType":4,"repost":{"id":"1144860170","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1643381040,"share":"https://ttm.financial/m/news/1144860170?lang=&edition=fundamental","pubTime":"2022-01-28 22:44","market":"us","language":"en","title":"Hot Chinese ADRs Dropped in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1144860170","media":"Tiger Newspress","summary":"Hot Chinese ADRs dropped in morning trading. Baidu, Pinduoduo, Ke Holdings, Bilibili, DiDi, Tal Educ","content":"<html><head></head><body><p>Hot Chinese ADRs dropped in morning trading. Baidu, Pinduoduo, Ke Holdings, Bilibili, DiDi, Tal Education, NIO and XPeng fell between 1% to 5%.<img src=\"https://static.tigerbbs.com/548c59d9ae453b022d396408529a0287\" tg-width=\"365\" tg-height=\"781\" width=\"100%\" height=\"auto\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hot Chinese ADRs Dropped in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHot Chinese ADRs Dropped in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-01-28 22:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Hot Chinese ADRs dropped in morning trading. Baidu, Pinduoduo, Ke Holdings, Bilibili, DiDi, Tal Education, NIO and XPeng fell between 1% to 5%.<img src=\"https://static.tigerbbs.com/548c59d9ae453b022d396408529a0287\" tg-width=\"365\" tg-height=\"781\" width=\"100%\" height=\"auto\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PDD":"拼多多","BABA":"阿里巴巴","DIDI":"滴滴(已退市)"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144860170","content_text":"Hot Chinese ADRs dropped in morning trading. Baidu, Pinduoduo, Ke Holdings, Bilibili, DiDi, Tal Education, NIO and XPeng fell between 1% to 5%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":501,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9099473238,"gmtCreate":1643419030019,"gmtModify":1676533818501,"author":{"id":"4101690391425510","authorId":"4101690391425510","name":"amybunny","avatar":"https://static.tigerbbs.com/eff2c98f1ea4d96950f8559f25c1c8f0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4101690391425510","authorIdStr":"4101690391425510"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NU\">$Nu Holdings Ltd.(NU)$</a>Should buy more share to lower the average cost or just leave itas it? What's your plan?&nbsp;","listText":"<a href=\"https://ttm.financial/S/NU\">$Nu Holdings Ltd.(NU)$</a>Should buy more share to lower the average cost or just leave itas it? What's your plan?&nbsp;","text":"$Nu Holdings Ltd.(NU)$Should buy more share to lower the average cost or just leave itas it? What's your plan?","images":[{"img":"https://static.itradeup.com/news/197452b789c3ebf9d7da55649cca54ba","width":"1125","height":"2196"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":1,"link":"https://ttm.financial/post/9099473238","isVote":1,"tweetType":1,"viewCount":1314,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4097562661170010","authorId":"4097562661170010","name":"noobInvestor","avatar":"https://community-static.tradeup.com/news/d104a307a36e9cc236579f70bc63ebba","crmLevel":4,"crmLevelSwitch":0,"idStr":"4097562661170010","authorIdStr":"4097562661170010"},"content":"in my opinion it is still overvalue at current price. maybe start to DCA at 4ish?","text":"in my opinion it is still overvalue at current price. maybe start to DCA at 4ish?","html":"in my opinion it is still overvalue at current price. maybe start to DCA at 4ish?"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9008180960,"gmtCreate":1641387952402,"gmtModify":1676533608920,"author":{"id":"4101690391425510","authorId":"4101690391425510","name":"amybunny","avatar":"https://static.tigerbbs.com/eff2c98f1ea4d96950f8559f25c1c8f0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4101690391425510","authorIdStr":"4101690391425510"},"themes":[],"htmlText":"Sit tight&nbsp;","listText":"Sit tight&nbsp;","text":"Sit tight","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008180960","repostId":"2201236325","repostType":4,"repost":{"id":"2201236325","kind":"highlight","pubTimestamp":1641385443,"share":"https://ttm.financial/m/news/2201236325?lang=&edition=fundamental","pubTime":"2022-01-05 20:24","market":"us","language":"en","title":"Is Now a Good Time to Buy Moderna Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2201236325","media":"Motley Fool","summary":"After dropping from record highs in August 2021, now may be a good time to assess Moderna's long-term value.","content":"<html><head></head><body><p>While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, <b>Moderna</b> (NASDAQ:MRNA) was granted Emergency Use Authorization for its coronavirus vaccine, and the stock increased by over 430% as positive news swirled over the jab&#39;s revolutionary mRNA technology. The company benefited financially from commercialization, and investors were rewarded with an additional stock price increase of over 120% in 2021. As we head into 2022 with a new variant, dubbed omicron, let&#39;s dig in to see if now is a good time to buy Moderna stock.</p><h2>What&#39;s the deal with the omicron variant?</h2><p>Since it was first detected in late November, the omicron variant has become the leading COVID strain in the U.S. According to data published by the Centers for Disease Control and Prevention (CDC), omicron now represents over 70% of new infections.</p><p>As Moderna&#39;s vaccine became more readily available and society began to experience its reopening, a number of organizations and private businesses required vaccination in order to enter. As of the end of July, 50% of the U.S. population was fully vaccinated against COVID-19. Three months later, the portion of fully vaccinated people increased to 58% by the end of October. As of Dec. 2021, approximately 60% of all Americans were fully vaccinated, and 21% of fully vaccinated Americans had received a booster shot. Although the swift rise in cases is certainly cause for concern, it could be argued that the omicron variant has also helped fuel an increase in vaccination rates.</p><p>According to the CDC&#39;s vaccination tracker, over 73 million Americans have received Moderna&#39;s vaccine and nearly 31 million people have received its booster. Early research has indicated that vaccines are significantly less effective against omicron without a booster. Moreover, antibodies in people who received two doses of Moderna&#39;s vaccine but not a booster were 50 times less effective against the omicron variant.</p><p>A recent study published in the U.K. found that protection against omicron decreased to just 10% within 20 weeks after a second dose of Moderna&#39;s vaccine. With a third booster, however, protection increased back up to 90%. The report also made a compelling case for Moderna&#39;s booster over other options. According to the study, protection against omicron was stronger in patients that received Moderna&#39;s booster after receiving <b>Pfizer</b>&#39;s vaccine, compared with those who received a third dose of Pfizer.</p><h2>What is the financial impact of the vaccine?</h2><p>Although it is difficult to gauge the potential for additional strains after omicron or whether annual booster shots will be recommended by the CDC, the U.S. and the global community still have a long road ahead in terms of increasing vaccination rates. Despite competition from Pfizer and <b>Johnson &amp; Johnson</b>, commercialization of the vaccine has already had a significant impact on Moderna&#39;s financials. If the disease becomes endemic, Moderna&#39;s vaccine should continue to serve as a lucrative revenue generator for the company going forward.</p><p>Investors can see the impact that the vaccine had on Moderna&#39;s business from its latest quarterly financial results. For the quarter ended Sept. 30, 2021, Moderna reported revenue of $5 billion compared to $157 million for the same period in 2020. Total revenue was $11.3 billion through the first nine months of 2021 compared to $232 million for the same period the prior year. The hyperbolic increase in revenue was largely due to commercialized sales of the company&#39;s COVID-19 vaccine.</p><p>Even more impressive is Moderna&#39;s profitability profile. The company reported net income of $3.3 billion for the quarter ended Sept. 30, 2021, compared to a net loss of $233 million for the same period in 2020. Net income was $7.3 billion for the nine months ended Sept. 30, 2021, compared to a net loss of $474 million during the same period in 2020. These profits have helped the company bolster its cash position, which sat at $15.3 billion as of Sept. 30, 2021. Increased profits can help Moderna invest in future clinical studies which could lead to further scientific breakthroughs or additional honing to existing medications, such as its COVID-19 vaccine.</p><h2>Now what?</h2><p>Moderna was not immune to the broader market pullbacks in November and December that affected high-flying tech stocks. Even if omicron wanes in 2022, there are possibilities for new strains or that the disease becomes endemic. In either scenario, Moderna is poised to benefit from any future administrations of its vaccine.</p><p>As of the time of this writing, Moderna has fallen over 50% from its 52-week in August 2021, equating to more than $98 billion of market capitalization being erased. At roughly nine times its trailing-12-month sales and a healthy profitability and cash profile, Moderna looks like a good buy going into 2022.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Now a Good Time to Buy Moderna Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Now a Good Time to Buy Moderna Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-05 20:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, Moderna (NASDAQ:MRNA...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4532":"文艺复兴科技持仓","MRNA":"Moderna, Inc.","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","CDC":"VictoryShares US EQ Income Enhanced Volatility Wtd ETF","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)"},"source_url":"https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201236325","content_text":"While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, Moderna (NASDAQ:MRNA) was granted Emergency Use Authorization for its coronavirus vaccine, and the stock increased by over 430% as positive news swirled over the jab's revolutionary mRNA technology. The company benefited financially from commercialization, and investors were rewarded with an additional stock price increase of over 120% in 2021. As we head into 2022 with a new variant, dubbed omicron, let's dig in to see if now is a good time to buy Moderna stock.What's the deal with the omicron variant?Since it was first detected in late November, the omicron variant has become the leading COVID strain in the U.S. According to data published by the Centers for Disease Control and Prevention (CDC), omicron now represents over 70% of new infections.As Moderna's vaccine became more readily available and society began to experience its reopening, a number of organizations and private businesses required vaccination in order to enter. As of the end of July, 50% of the U.S. population was fully vaccinated against COVID-19. Three months later, the portion of fully vaccinated people increased to 58% by the end of October. As of Dec. 2021, approximately 60% of all Americans were fully vaccinated, and 21% of fully vaccinated Americans had received a booster shot. Although the swift rise in cases is certainly cause for concern, it could be argued that the omicron variant has also helped fuel an increase in vaccination rates.According to the CDC's vaccination tracker, over 73 million Americans have received Moderna's vaccine and nearly 31 million people have received its booster. Early research has indicated that vaccines are significantly less effective against omicron without a booster. Moreover, antibodies in people who received two doses of Moderna's vaccine but not a booster were 50 times less effective against the omicron variant.A recent study published in the U.K. found that protection against omicron decreased to just 10% within 20 weeks after a second dose of Moderna's vaccine. With a third booster, however, protection increased back up to 90%. The report also made a compelling case for Moderna's booster over other options. According to the study, protection against omicron was stronger in patients that received Moderna's booster after receiving Pfizer's vaccine, compared with those who received a third dose of Pfizer.What is the financial impact of the vaccine?Although it is difficult to gauge the potential for additional strains after omicron or whether annual booster shots will be recommended by the CDC, the U.S. and the global community still have a long road ahead in terms of increasing vaccination rates. Despite competition from Pfizer and Johnson & Johnson, commercialization of the vaccine has already had a significant impact on Moderna's financials. If the disease becomes endemic, Moderna's vaccine should continue to serve as a lucrative revenue generator for the company going forward.Investors can see the impact that the vaccine had on Moderna's business from its latest quarterly financial results. For the quarter ended Sept. 30, 2021, Moderna reported revenue of $5 billion compared to $157 million for the same period in 2020. Total revenue was $11.3 billion through the first nine months of 2021 compared to $232 million for the same period the prior year. The hyperbolic increase in revenue was largely due to commercialized sales of the company's COVID-19 vaccine.Even more impressive is Moderna's profitability profile. The company reported net income of $3.3 billion for the quarter ended Sept. 30, 2021, compared to a net loss of $233 million for the same period in 2020. Net income was $7.3 billion for the nine months ended Sept. 30, 2021, compared to a net loss of $474 million during the same period in 2020. These profits have helped the company bolster its cash position, which sat at $15.3 billion as of Sept. 30, 2021. Increased profits can help Moderna invest in future clinical studies which could lead to further scientific breakthroughs or additional honing to existing medications, such as its COVID-19 vaccine.Now what?Moderna was not immune to the broader market pullbacks in November and December that affected high-flying tech stocks. Even if omicron wanes in 2022, there are possibilities for new strains or that the disease becomes endemic. In either scenario, Moderna is poised to benefit from any future administrations of its vaccine.As of the time of this writing, Moderna has fallen over 50% from its 52-week in August 2021, equating to more than $98 billion of market capitalization being erased. At roughly nine times its trailing-12-month sales and a healthy profitability and cash profile, Moderna looks like a good buy going into 2022.","news_type":1},"isVote":1,"tweetType":1,"viewCount":545,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9003100027,"gmtCreate":1640904118875,"gmtModify":1676533552159,"author":{"id":"4101690391425510","authorId":"4101690391425510","name":"amybunny","avatar":"https://static.tigerbbs.com/eff2c98f1ea4d96950f8559f25c1c8f0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4101690391425510","authorIdStr":"4101690391425510"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9003100027","repostId":"1124654828","repostType":2,"repost":{"id":"1124654828","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640867553,"share":"https://ttm.financial/m/news/1124654828?lang=&edition=fundamental","pubTime":"2021-12-30 20:32","market":"us","language":"en","title":"Toplines Before US Market Open on Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=1124654828","media":"Tiger Newspress","summary":"U.S. stock index futures rose marginally on Thursday, as easing worries around the Omicron variant p","content":"<html><head></head><body><p>U.S. stock index futures rose marginally on Thursday, as easing worries around the Omicron variant put the S&amp;P 500 and the Dow on track to extend record-setting runs, with focus turning to a weekly jobless report to gauge the country&#39;s economic health.</p><p>At 8:33 a.m. ET, Dow e-minis  were up 51points, or 0.14%, S&amp;P 500 e-minis  were up 6.5 points, or 0.14%, and Nasdaq 100 e-minis  were up  23.25points, or 0.14%.</p><p><img src=\"https://static.tigerbbs.com/cd072b4fef09af886d7362cbdbad3381\" tg-width=\"360\" tg-height=\"165\" referrerpolicy=\"no-referrer\"/></p><p>Initial filings for unemployment insurance dipped last week and remained close to their lowest level in more than 50 years, the Labor Department reported Thursday.</p><p>Jobless claims for the week ended Dec. 25 totaled 198,000, less than the 205,000 Dow Jones forecast and a dip of 8,000 from the previous period.</p><p>When adjusting for weekly volatility, the four-week moving average for claims came to 199,250, the lowest level since Oct. 25, 1969.</p><p><b>Stocks making the biggest moves premarket: </b></p><p>Biogen (BIIB) – Biogen slid 6.5% in the premarket after Samsung denied a report in the Korea Economic Daily publication that it was in talks to buy Biogen and combine it with its biotech unit. Biogen shares had jumped 9.5% Wednesday on that report.</p><p></p><p>JetBlue (JBLU) – The airline cut nearly 1,300 flights from its schedule through January 13, as it deals with a surge in Covid-19 infections among its flight staff. JetBlue was down 1% in premarket action.</p><p></p><p>Didi Global (DIDI) – The China-based ride-hailing company’s shares slid 3.2% in premarket trading after it reported a 1.7% decline in third-quarter revenue and a loss of $4.7 billion. Didi had slumped 8.2% Wednesday and has fallen in 12 of the past 15 trading days.</p><p></p><p>R.R. Donnelley (RRD) – The business communications and marketing services company received an unsolicited, non-binding acquisition proposal at $11 per share in cash. R.R. Donnelley already has an agreement in place to be acquired by affiliates of private equity firm Chatham Asset Management for $10.85 per share. Donnelley shares jumped 3.1% in premarket trading.</p><p></p><p>Virgin Orbit (VORB) – The satellite-launching spin-off of space travel company Virgin Galactic will begin trading under the Virgin Orbit name and ticker on Nasdaq today after shareholders of blank-check company NextGen Acquisition Corp. II approved the merger earlier this week.</p><p></p><p>Micron Technology (MU) – The memory chip maker’s stock lost 1.5% in the premarket after it warned that Covid-19 curbs in China’s Xian tech hub would impact production. Samsung Electronics – which is also one of the world’s biggest memory chip makers, issued a similar warning.</p><p></p><p>Johnson &amp; Johnson (JNJ) – A booster dose of the J&amp;J Covid-19 vaccine was found to be 85% effective in preventing hospitalizations in a South African study, which has yet to be peer-reviewed.</p><p></p><p>Microstrategy (MSTR) – The business analytics company’s stock rose 1.1% in the premarket, tracking a rise in bitcoin prices. Microstrategy has bitcoin holdings worth several billion dollars on its balance sheet.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Thursday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Thursday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-30 20:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>U.S. stock index futures rose marginally on Thursday, as easing worries around the Omicron variant put the S&amp;P 500 and the Dow on track to extend record-setting runs, with focus turning to a weekly jobless report to gauge the country&#39;s economic health.</p><p>At 8:33 a.m. ET, Dow e-minis  were up 51points, or 0.14%, S&amp;P 500 e-minis  were up 6.5 points, or 0.14%, and Nasdaq 100 e-minis  were up  23.25points, or 0.14%.</p><p><img src=\"https://static.tigerbbs.com/cd072b4fef09af886d7362cbdbad3381\" tg-width=\"360\" tg-height=\"165\" referrerpolicy=\"no-referrer\"/></p><p>Initial filings for unemployment insurance dipped last week and remained close to their lowest level in more than 50 years, the Labor Department reported Thursday.</p><p>Jobless claims for the week ended Dec. 25 totaled 198,000, less than the 205,000 Dow Jones forecast and a dip of 8,000 from the previous period.</p><p>When adjusting for weekly volatility, the four-week moving average for claims came to 199,250, the lowest level since Oct. 25, 1969.</p><p><b>Stocks making the biggest moves premarket: </b></p><p>Biogen (BIIB) – Biogen slid 6.5% in the premarket after Samsung denied a report in the Korea Economic Daily publication that it was in talks to buy Biogen and combine it with its biotech unit. Biogen shares had jumped 9.5% Wednesday on that report.</p><p></p><p>JetBlue (JBLU) – The airline cut nearly 1,300 flights from its schedule through January 13, as it deals with a surge in Covid-19 infections among its flight staff. JetBlue was down 1% in premarket action.</p><p></p><p>Didi Global (DIDI) – The China-based ride-hailing company’s shares slid 3.2% in premarket trading after it reported a 1.7% decline in third-quarter revenue and a loss of $4.7 billion. Didi had slumped 8.2% Wednesday and has fallen in 12 of the past 15 trading days.</p><p></p><p>R.R. Donnelley (RRD) – The business communications and marketing services company received an unsolicited, non-binding acquisition proposal at $11 per share in cash. R.R. Donnelley already has an agreement in place to be acquired by affiliates of private equity firm Chatham Asset Management for $10.85 per share. Donnelley shares jumped 3.1% in premarket trading.</p><p></p><p>Virgin Orbit (VORB) – The satellite-launching spin-off of space travel company Virgin Galactic will begin trading under the Virgin Orbit name and ticker on Nasdaq today after shareholders of blank-check company NextGen Acquisition Corp. II approved the merger earlier this week.</p><p></p><p>Micron Technology (MU) – The memory chip maker’s stock lost 1.5% in the premarket after it warned that Covid-19 curbs in China’s Xian tech hub would impact production. Samsung Electronics – which is also one of the world’s biggest memory chip makers, issued a similar warning.</p><p></p><p>Johnson &amp; Johnson (JNJ) – A booster dose of the J&amp;J Covid-19 vaccine was found to be 85% effective in preventing hospitalizations in a South African study, which has yet to be peer-reviewed.</p><p></p><p>Microstrategy (MSTR) – The business analytics company’s stock rose 1.1% in the premarket, tracking a rise in bitcoin prices. Microstrategy has bitcoin holdings worth several billion dollars on its balance sheet.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite","JBLU":"捷蓝航空","RRD":"当纳利","DIDI":"滴滴(已退市)",".DJI":"道琼斯","VORB":"维珍轨道","BIIB":"渤健公司","MU":"美光科技"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124654828","content_text":"U.S. stock index futures rose marginally on Thursday, as easing worries around the Omicron variant put the S&P 500 and the Dow on track to extend record-setting runs, with focus turning to a weekly jobless report to gauge the country's economic health.At 8:33 a.m. ET, Dow e-minis  were up 51points, or 0.14%, S&P 500 e-minis  were up 6.5 points, or 0.14%, and Nasdaq 100 e-minis  were up  23.25points, or 0.14%.Initial filings for unemployment insurance dipped last week and remained close to their lowest level in more than 50 years, the Labor Department reported Thursday.Jobless claims for the week ended Dec. 25 totaled 198,000, less than the 205,000 Dow Jones forecast and a dip of 8,000 from the previous period.When adjusting for weekly volatility, the four-week moving average for claims came to 199,250, the lowest level since Oct. 25, 1969.Stocks making the biggest moves premarket: Biogen (BIIB) – Biogen slid 6.5% in the premarket after Samsung denied a report in the Korea Economic Daily publication that it was in talks to buy Biogen and combine it with its biotech unit. Biogen shares had jumped 9.5% Wednesday on that report.JetBlue (JBLU) – The airline cut nearly 1,300 flights from its schedule through January 13, as it deals with a surge in Covid-19 infections among its flight staff. JetBlue was down 1% in premarket action.Didi Global (DIDI) – The China-based ride-hailing company’s shares slid 3.2% in premarket trading after it reported a 1.7% decline in third-quarter revenue and a loss of $4.7 billion. Didi had slumped 8.2% Wednesday and has fallen in 12 of the past 15 trading days.R.R. Donnelley (RRD) – The business communications and marketing services company received an unsolicited, non-binding acquisition proposal at $11 per share in cash. R.R. Donnelley already has an agreement in place to be acquired by affiliates of private equity firm Chatham Asset Management for $10.85 per share. Donnelley shares jumped 3.1% in premarket trading.Virgin Orbit (VORB) – The satellite-launching spin-off of space travel company Virgin Galactic will begin trading under the Virgin Orbit name and ticker on Nasdaq today after shareholders of blank-check company NextGen Acquisition Corp. II approved the merger earlier this week.Micron Technology (MU) – The memory chip maker’s stock lost 1.5% in the premarket after it warned that Covid-19 curbs in China’s Xian tech hub would impact production. Samsung Electronics – which is also one of the world’s biggest memory chip makers, issued a similar warning.Johnson & Johnson (JNJ) – A booster dose of the J&J Covid-19 vaccine was found to be 85% effective in preventing hospitalizations in a South African study, which has yet to be peer-reviewed.Microstrategy (MSTR) – The business analytics company’s stock rose 1.1% in the premarket, tracking a rise in bitcoin prices. Microstrategy has bitcoin holdings worth several billion dollars on its balance sheet.","news_type":1},"isVote":1,"tweetType":1,"viewCount":468,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":9099473238,"gmtCreate":1643419030019,"gmtModify":1676533818501,"author":{"id":"4101690391425510","authorId":"4101690391425510","name":"amybunny","avatar":"https://static.tigerbbs.com/eff2c98f1ea4d96950f8559f25c1c8f0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4101690391425510","authorIdStr":"4101690391425510"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NU\">$Nu Holdings Ltd.(NU)$</a>Should buy more share to lower the average cost or just leave itas it? What's your plan?&nbsp;","listText":"<a href=\"https://ttm.financial/S/NU\">$Nu Holdings Ltd.(NU)$</a>Should buy more share to lower the average cost or just leave itas it? What's your plan?&nbsp;","text":"$Nu Holdings Ltd.(NU)$Should buy more share to lower the average cost or just leave itas it? What's your plan?","images":[{"img":"https://static.itradeup.com/news/197452b789c3ebf9d7da55649cca54ba","width":"1125","height":"2196"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":1,"link":"https://ttm.financial/post/9099473238","isVote":1,"tweetType":1,"viewCount":1314,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4097562661170010","authorId":"4097562661170010","name":"noobInvestor","avatar":"https://community-static.tradeup.com/news/d104a307a36e9cc236579f70bc63ebba","crmLevel":4,"crmLevelSwitch":0,"idStr":"4097562661170010","authorIdStr":"4097562661170010"},"content":"in my opinion it is still overvalue at current price. maybe start to DCA at 4ish?","text":"in my opinion it is still overvalue at current price. maybe start to DCA at 4ish?","html":"in my opinion it is still overvalue at current price. maybe start to DCA at 4ish?"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9099475962,"gmtCreate":1643419570470,"gmtModify":1676533818623,"author":{"id":"4101690391425510","authorId":"4101690391425510","name":"amybunny","avatar":"https://static.tigerbbs.com/eff2c98f1ea4d96950f8559f25c1c8f0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4101690391425510","authorIdStr":"4101690391425510"},"themes":[],"htmlText":"Unit confident to buy any of this stock&nbsp;","listText":"Unit confident to buy any of this stock&nbsp;","text":"Unit confident to buy any of this stock","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9099475962","repostId":"1144860170","repostType":4,"repost":{"id":"1144860170","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1643381040,"share":"https://ttm.financial/m/news/1144860170?lang=&edition=fundamental","pubTime":"2022-01-28 22:44","market":"us","language":"en","title":"Hot Chinese ADRs Dropped in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1144860170","media":"Tiger Newspress","summary":"Hot Chinese ADRs dropped in morning trading. Baidu, Pinduoduo, Ke Holdings, Bilibili, DiDi, Tal Educ","content":"<html><head></head><body><p>Hot Chinese ADRs dropped in morning trading. Baidu, Pinduoduo, Ke Holdings, Bilibili, DiDi, Tal Education, NIO and XPeng fell between 1% to 5%.<img src=\"https://static.tigerbbs.com/548c59d9ae453b022d396408529a0287\" tg-width=\"365\" tg-height=\"781\" width=\"100%\" height=\"auto\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hot Chinese ADRs Dropped in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHot Chinese ADRs Dropped in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-01-28 22:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Hot Chinese ADRs dropped in morning trading. Baidu, Pinduoduo, Ke Holdings, Bilibili, DiDi, Tal Education, NIO and XPeng fell between 1% to 5%.<img src=\"https://static.tigerbbs.com/548c59d9ae453b022d396408529a0287\" tg-width=\"365\" tg-height=\"781\" width=\"100%\" height=\"auto\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PDD":"拼多多","BABA":"阿里巴巴","DIDI":"滴滴(已退市)"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144860170","content_text":"Hot Chinese ADRs dropped in morning trading. Baidu, Pinduoduo, Ke Holdings, Bilibili, DiDi, Tal Education, NIO and XPeng fell between 1% to 5%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":501,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9003100027,"gmtCreate":1640904118875,"gmtModify":1676533552159,"author":{"id":"4101690391425510","authorId":"4101690391425510","name":"amybunny","avatar":"https://static.tigerbbs.com/eff2c98f1ea4d96950f8559f25c1c8f0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4101690391425510","authorIdStr":"4101690391425510"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9003100027","repostId":"1124654828","repostType":2,"repost":{"id":"1124654828","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640867553,"share":"https://ttm.financial/m/news/1124654828?lang=&edition=fundamental","pubTime":"2021-12-30 20:32","market":"us","language":"en","title":"Toplines Before US Market Open on Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=1124654828","media":"Tiger Newspress","summary":"U.S. stock index futures rose marginally on Thursday, as easing worries around the Omicron variant p","content":"<html><head></head><body><p>U.S. stock index futures rose marginally on Thursday, as easing worries around the Omicron variant put the S&amp;P 500 and the Dow on track to extend record-setting runs, with focus turning to a weekly jobless report to gauge the country&#39;s economic health.</p><p>At 8:33 a.m. ET, Dow e-minis  were up 51points, or 0.14%, S&amp;P 500 e-minis  were up 6.5 points, or 0.14%, and Nasdaq 100 e-minis  were up  23.25points, or 0.14%.</p><p><img src=\"https://static.tigerbbs.com/cd072b4fef09af886d7362cbdbad3381\" tg-width=\"360\" tg-height=\"165\" referrerpolicy=\"no-referrer\"/></p><p>Initial filings for unemployment insurance dipped last week and remained close to their lowest level in more than 50 years, the Labor Department reported Thursday.</p><p>Jobless claims for the week ended Dec. 25 totaled 198,000, less than the 205,000 Dow Jones forecast and a dip of 8,000 from the previous period.</p><p>When adjusting for weekly volatility, the four-week moving average for claims came to 199,250, the lowest level since Oct. 25, 1969.</p><p><b>Stocks making the biggest moves premarket: </b></p><p>Biogen (BIIB) – Biogen slid 6.5% in the premarket after Samsung denied a report in the Korea Economic Daily publication that it was in talks to buy Biogen and combine it with its biotech unit. Biogen shares had jumped 9.5% Wednesday on that report.</p><p></p><p>JetBlue (JBLU) – The airline cut nearly 1,300 flights from its schedule through January 13, as it deals with a surge in Covid-19 infections among its flight staff. JetBlue was down 1% in premarket action.</p><p></p><p>Didi Global (DIDI) – The China-based ride-hailing company’s shares slid 3.2% in premarket trading after it reported a 1.7% decline in third-quarter revenue and a loss of $4.7 billion. Didi had slumped 8.2% Wednesday and has fallen in 12 of the past 15 trading days.</p><p></p><p>R.R. Donnelley (RRD) – The business communications and marketing services company received an unsolicited, non-binding acquisition proposal at $11 per share in cash. R.R. Donnelley already has an agreement in place to be acquired by affiliates of private equity firm Chatham Asset Management for $10.85 per share. Donnelley shares jumped 3.1% in premarket trading.</p><p></p><p>Virgin Orbit (VORB) – The satellite-launching spin-off of space travel company Virgin Galactic will begin trading under the Virgin Orbit name and ticker on Nasdaq today after shareholders of blank-check company NextGen Acquisition Corp. II approved the merger earlier this week.</p><p></p><p>Micron Technology (MU) – The memory chip maker’s stock lost 1.5% in the premarket after it warned that Covid-19 curbs in China’s Xian tech hub would impact production. Samsung Electronics – which is also one of the world’s biggest memory chip makers, issued a similar warning.</p><p></p><p>Johnson &amp; Johnson (JNJ) – A booster dose of the J&amp;J Covid-19 vaccine was found to be 85% effective in preventing hospitalizations in a South African study, which has yet to be peer-reviewed.</p><p></p><p>Microstrategy (MSTR) – The business analytics company’s stock rose 1.1% in the premarket, tracking a rise in bitcoin prices. Microstrategy has bitcoin holdings worth several billion dollars on its balance sheet.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Thursday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Thursday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-30 20:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>U.S. stock index futures rose marginally on Thursday, as easing worries around the Omicron variant put the S&amp;P 500 and the Dow on track to extend record-setting runs, with focus turning to a weekly jobless report to gauge the country&#39;s economic health.</p><p>At 8:33 a.m. ET, Dow e-minis  were up 51points, or 0.14%, S&amp;P 500 e-minis  were up 6.5 points, or 0.14%, and Nasdaq 100 e-minis  were up  23.25points, or 0.14%.</p><p><img src=\"https://static.tigerbbs.com/cd072b4fef09af886d7362cbdbad3381\" tg-width=\"360\" tg-height=\"165\" referrerpolicy=\"no-referrer\"/></p><p>Initial filings for unemployment insurance dipped last week and remained close to their lowest level in more than 50 years, the Labor Department reported Thursday.</p><p>Jobless claims for the week ended Dec. 25 totaled 198,000, less than the 205,000 Dow Jones forecast and a dip of 8,000 from the previous period.</p><p>When adjusting for weekly volatility, the four-week moving average for claims came to 199,250, the lowest level since Oct. 25, 1969.</p><p><b>Stocks making the biggest moves premarket: </b></p><p>Biogen (BIIB) – Biogen slid 6.5% in the premarket after Samsung denied a report in the Korea Economic Daily publication that it was in talks to buy Biogen and combine it with its biotech unit. Biogen shares had jumped 9.5% Wednesday on that report.</p><p></p><p>JetBlue (JBLU) – The airline cut nearly 1,300 flights from its schedule through January 13, as it deals with a surge in Covid-19 infections among its flight staff. JetBlue was down 1% in premarket action.</p><p></p><p>Didi Global (DIDI) – The China-based ride-hailing company’s shares slid 3.2% in premarket trading after it reported a 1.7% decline in third-quarter revenue and a loss of $4.7 billion. Didi had slumped 8.2% Wednesday and has fallen in 12 of the past 15 trading days.</p><p></p><p>R.R. Donnelley (RRD) – The business communications and marketing services company received an unsolicited, non-binding acquisition proposal at $11 per share in cash. R.R. Donnelley already has an agreement in place to be acquired by affiliates of private equity firm Chatham Asset Management for $10.85 per share. Donnelley shares jumped 3.1% in premarket trading.</p><p></p><p>Virgin Orbit (VORB) – The satellite-launching spin-off of space travel company Virgin Galactic will begin trading under the Virgin Orbit name and ticker on Nasdaq today after shareholders of blank-check company NextGen Acquisition Corp. II approved the merger earlier this week.</p><p></p><p>Micron Technology (MU) – The memory chip maker’s stock lost 1.5% in the premarket after it warned that Covid-19 curbs in China’s Xian tech hub would impact production. Samsung Electronics – which is also one of the world’s biggest memory chip makers, issued a similar warning.</p><p></p><p>Johnson &amp; Johnson (JNJ) – A booster dose of the J&amp;J Covid-19 vaccine was found to be 85% effective in preventing hospitalizations in a South African study, which has yet to be peer-reviewed.</p><p></p><p>Microstrategy (MSTR) – The business analytics company’s stock rose 1.1% in the premarket, tracking a rise in bitcoin prices. Microstrategy has bitcoin holdings worth several billion dollars on its balance sheet.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite","JBLU":"捷蓝航空","RRD":"当纳利","DIDI":"滴滴(已退市)",".DJI":"道琼斯","VORB":"维珍轨道","BIIB":"渤健公司","MU":"美光科技"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124654828","content_text":"U.S. stock index futures rose marginally on Thursday, as easing worries around the Omicron variant put the S&P 500 and the Dow on track to extend record-setting runs, with focus turning to a weekly jobless report to gauge the country's economic health.At 8:33 a.m. ET, Dow e-minis  were up 51points, or 0.14%, S&P 500 e-minis  were up 6.5 points, or 0.14%, and Nasdaq 100 e-minis  were up  23.25points, or 0.14%.Initial filings for unemployment insurance dipped last week and remained close to their lowest level in more than 50 years, the Labor Department reported Thursday.Jobless claims for the week ended Dec. 25 totaled 198,000, less than the 205,000 Dow Jones forecast and a dip of 8,000 from the previous period.When adjusting for weekly volatility, the four-week moving average for claims came to 199,250, the lowest level since Oct. 25, 1969.Stocks making the biggest moves premarket: Biogen (BIIB) – Biogen slid 6.5% in the premarket after Samsung denied a report in the Korea Economic Daily publication that it was in talks to buy Biogen and combine it with its biotech unit. Biogen shares had jumped 9.5% Wednesday on that report.JetBlue (JBLU) – The airline cut nearly 1,300 flights from its schedule through January 13, as it deals with a surge in Covid-19 infections among its flight staff. JetBlue was down 1% in premarket action.Didi Global (DIDI) – The China-based ride-hailing company’s shares slid 3.2% in premarket trading after it reported a 1.7% decline in third-quarter revenue and a loss of $4.7 billion. Didi had slumped 8.2% Wednesday and has fallen in 12 of the past 15 trading days.R.R. Donnelley (RRD) – The business communications and marketing services company received an unsolicited, non-binding acquisition proposal at $11 per share in cash. R.R. Donnelley already has an agreement in place to be acquired by affiliates of private equity firm Chatham Asset Management for $10.85 per share. Donnelley shares jumped 3.1% in premarket trading.Virgin Orbit (VORB) – The satellite-launching spin-off of space travel company Virgin Galactic will begin trading under the Virgin Orbit name and ticker on Nasdaq today after shareholders of blank-check company NextGen Acquisition Corp. II approved the merger earlier this week.Micron Technology (MU) – The memory chip maker’s stock lost 1.5% in the premarket after it warned that Covid-19 curbs in China’s Xian tech hub would impact production. Samsung Electronics – which is also one of the world’s biggest memory chip makers, issued a similar warning.Johnson & Johnson (JNJ) – A booster dose of the J&J Covid-19 vaccine was found to be 85% effective in preventing hospitalizations in a South African study, which has yet to be peer-reviewed.Microstrategy (MSTR) – The business analytics company’s stock rose 1.1% in the premarket, tracking a rise in bitcoin prices. Microstrategy has bitcoin holdings worth several billion dollars on its balance sheet.","news_type":1},"isVote":1,"tweetType":1,"viewCount":468,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9987012142,"gmtCreate":1667778603486,"gmtModify":1676537960702,"author":{"id":"4101690391425510","authorId":"4101690391425510","name":"amybunny","avatar":"https://static.tigerbbs.com/eff2c98f1ea4d96950f8559f25c1c8f0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4101690391425510","authorIdStr":"4101690391425510"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/KO\">$Coca-Cola(KO)$</a>[Cool]&nbsp;","listText":"<a href=\"https://ttm.financial/S/KO\">$Coca-Cola(KO)$</a>[Cool]&nbsp;","text":"$Coca-Cola(KO)$[Cool]","images":[{"img":"https://community-static.tradeup.com/news/277225a60cc4e78705823b6c7965fc4c","width":"1179","height":"2316"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9987012142","isVote":1,"tweetType":1,"viewCount":209,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9988313961,"gmtCreate":1666664985053,"gmtModify":1676537786147,"author":{"id":"4101690391425510","authorId":"4101690391425510","name":"amybunny","avatar":"https://static.tigerbbs.com/eff2c98f1ea4d96950f8559f25c1c8f0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4101690391425510","authorIdStr":"4101690391425510"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/STI.SI\">$Straits Times Index(STI.SI)$</a>good to buy?","listText":"<a href=\"https://ttm.financial/S/STI.SI\">$Straits Times Index(STI.SI)$</a>good to buy?","text":"$Straits Times Index(STI.SI)$good to buy?","images":[{"img":"https://community-static.tradeup.com/news/113b2a06bb22ab09d533f5a466b895ba","width":"1125","height":"1744"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9988313961","isVote":1,"tweetType":1,"viewCount":246,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9008180960,"gmtCreate":1641387952402,"gmtModify":1676533608920,"author":{"id":"4101690391425510","authorId":"4101690391425510","name":"amybunny","avatar":"https://static.tigerbbs.com/eff2c98f1ea4d96950f8559f25c1c8f0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4101690391425510","authorIdStr":"4101690391425510"},"themes":[],"htmlText":"Sit tight&nbsp;","listText":"Sit tight&nbsp;","text":"Sit tight","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008180960","repostId":"2201236325","repostType":4,"repost":{"id":"2201236325","kind":"highlight","pubTimestamp":1641385443,"share":"https://ttm.financial/m/news/2201236325?lang=&edition=fundamental","pubTime":"2022-01-05 20:24","market":"us","language":"en","title":"Is Now a Good Time to Buy Moderna Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2201236325","media":"Motley Fool","summary":"After dropping from record highs in August 2021, now may be a good time to assess Moderna's long-term value.","content":"<html><head></head><body><p>While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, <b>Moderna</b> (NASDAQ:MRNA) was granted Emergency Use Authorization for its coronavirus vaccine, and the stock increased by over 430% as positive news swirled over the jab&#39;s revolutionary mRNA technology. The company benefited financially from commercialization, and investors were rewarded with an additional stock price increase of over 120% in 2021. As we head into 2022 with a new variant, dubbed omicron, let&#39;s dig in to see if now is a good time to buy Moderna stock.</p><h2>What&#39;s the deal with the omicron variant?</h2><p>Since it was first detected in late November, the omicron variant has become the leading COVID strain in the U.S. According to data published by the Centers for Disease Control and Prevention (CDC), omicron now represents over 70% of new infections.</p><p>As Moderna&#39;s vaccine became more readily available and society began to experience its reopening, a number of organizations and private businesses required vaccination in order to enter. As of the end of July, 50% of the U.S. population was fully vaccinated against COVID-19. Three months later, the portion of fully vaccinated people increased to 58% by the end of October. As of Dec. 2021, approximately 60% of all Americans were fully vaccinated, and 21% of fully vaccinated Americans had received a booster shot. Although the swift rise in cases is certainly cause for concern, it could be argued that the omicron variant has also helped fuel an increase in vaccination rates.</p><p>According to the CDC&#39;s vaccination tracker, over 73 million Americans have received Moderna&#39;s vaccine and nearly 31 million people have received its booster. Early research has indicated that vaccines are significantly less effective against omicron without a booster. Moreover, antibodies in people who received two doses of Moderna&#39;s vaccine but not a booster were 50 times less effective against the omicron variant.</p><p>A recent study published in the U.K. found that protection against omicron decreased to just 10% within 20 weeks after a second dose of Moderna&#39;s vaccine. With a third booster, however, protection increased back up to 90%. The report also made a compelling case for Moderna&#39;s booster over other options. According to the study, protection against omicron was stronger in patients that received Moderna&#39;s booster after receiving <b>Pfizer</b>&#39;s vaccine, compared with those who received a third dose of Pfizer.</p><h2>What is the financial impact of the vaccine?</h2><p>Although it is difficult to gauge the potential for additional strains after omicron or whether annual booster shots will be recommended by the CDC, the U.S. and the global community still have a long road ahead in terms of increasing vaccination rates. Despite competition from Pfizer and <b>Johnson &amp; Johnson</b>, commercialization of the vaccine has already had a significant impact on Moderna&#39;s financials. If the disease becomes endemic, Moderna&#39;s vaccine should continue to serve as a lucrative revenue generator for the company going forward.</p><p>Investors can see the impact that the vaccine had on Moderna&#39;s business from its latest quarterly financial results. For the quarter ended Sept. 30, 2021, Moderna reported revenue of $5 billion compared to $157 million for the same period in 2020. Total revenue was $11.3 billion through the first nine months of 2021 compared to $232 million for the same period the prior year. The hyperbolic increase in revenue was largely due to commercialized sales of the company&#39;s COVID-19 vaccine.</p><p>Even more impressive is Moderna&#39;s profitability profile. The company reported net income of $3.3 billion for the quarter ended Sept. 30, 2021, compared to a net loss of $233 million for the same period in 2020. Net income was $7.3 billion for the nine months ended Sept. 30, 2021, compared to a net loss of $474 million during the same period in 2020. These profits have helped the company bolster its cash position, which sat at $15.3 billion as of Sept. 30, 2021. Increased profits can help Moderna invest in future clinical studies which could lead to further scientific breakthroughs or additional honing to existing medications, such as its COVID-19 vaccine.</p><h2>Now what?</h2><p>Moderna was not immune to the broader market pullbacks in November and December that affected high-flying tech stocks. Even if omicron wanes in 2022, there are possibilities for new strains or that the disease becomes endemic. In either scenario, Moderna is poised to benefit from any future administrations of its vaccine.</p><p>As of the time of this writing, Moderna has fallen over 50% from its 52-week in August 2021, equating to more than $98 billion of market capitalization being erased. At roughly nine times its trailing-12-month sales and a healthy profitability and cash profile, Moderna looks like a good buy going into 2022.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Now a Good Time to Buy Moderna Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Now a Good Time to Buy Moderna Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-05 20:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, Moderna (NASDAQ:MRNA...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4532":"文艺复兴科技持仓","MRNA":"Moderna, Inc.","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","CDC":"VictoryShares US EQ Income Enhanced Volatility Wtd ETF","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)"},"source_url":"https://www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201236325","content_text":"While COVID-19 invoked economic and social hardships, the pandemic has also helped fuel some of the most impressive technological and scientific developments of our time. In 2020, Moderna (NASDAQ:MRNA) was granted Emergency Use Authorization for its coronavirus vaccine, and the stock increased by over 430% as positive news swirled over the jab's revolutionary mRNA technology. The company benefited financially from commercialization, and investors were rewarded with an additional stock price increase of over 120% in 2021. As we head into 2022 with a new variant, dubbed omicron, let's dig in to see if now is a good time to buy Moderna stock.What's the deal with the omicron variant?Since it was first detected in late November, the omicron variant has become the leading COVID strain in the U.S. According to data published by the Centers for Disease Control and Prevention (CDC), omicron now represents over 70% of new infections.As Moderna's vaccine became more readily available and society began to experience its reopening, a number of organizations and private businesses required vaccination in order to enter. As of the end of July, 50% of the U.S. population was fully vaccinated against COVID-19. Three months later, the portion of fully vaccinated people increased to 58% by the end of October. As of Dec. 2021, approximately 60% of all Americans were fully vaccinated, and 21% of fully vaccinated Americans had received a booster shot. Although the swift rise in cases is certainly cause for concern, it could be argued that the omicron variant has also helped fuel an increase in vaccination rates.According to the CDC's vaccination tracker, over 73 million Americans have received Moderna's vaccine and nearly 31 million people have received its booster. Early research has indicated that vaccines are significantly less effective against omicron without a booster. Moreover, antibodies in people who received two doses of Moderna's vaccine but not a booster were 50 times less effective against the omicron variant.A recent study published in the U.K. found that protection against omicron decreased to just 10% within 20 weeks after a second dose of Moderna's vaccine. With a third booster, however, protection increased back up to 90%. The report also made a compelling case for Moderna's booster over other options. According to the study, protection against omicron was stronger in patients that received Moderna's booster after receiving Pfizer's vaccine, compared with those who received a third dose of Pfizer.What is the financial impact of the vaccine?Although it is difficult to gauge the potential for additional strains after omicron or whether annual booster shots will be recommended by the CDC, the U.S. and the global community still have a long road ahead in terms of increasing vaccination rates. Despite competition from Pfizer and Johnson & Johnson, commercialization of the vaccine has already had a significant impact on Moderna's financials. If the disease becomes endemic, Moderna's vaccine should continue to serve as a lucrative revenue generator for the company going forward.Investors can see the impact that the vaccine had on Moderna's business from its latest quarterly financial results. For the quarter ended Sept. 30, 2021, Moderna reported revenue of $5 billion compared to $157 million for the same period in 2020. Total revenue was $11.3 billion through the first nine months of 2021 compared to $232 million for the same period the prior year. The hyperbolic increase in revenue was largely due to commercialized sales of the company's COVID-19 vaccine.Even more impressive is Moderna's profitability profile. The company reported net income of $3.3 billion for the quarter ended Sept. 30, 2021, compared to a net loss of $233 million for the same period in 2020. Net income was $7.3 billion for the nine months ended Sept. 30, 2021, compared to a net loss of $474 million during the same period in 2020. These profits have helped the company bolster its cash position, which sat at $15.3 billion as of Sept. 30, 2021. Increased profits can help Moderna invest in future clinical studies which could lead to further scientific breakthroughs or additional honing to existing medications, such as its COVID-19 vaccine.Now what?Moderna was not immune to the broader market pullbacks in November and December that affected high-flying tech stocks. Even if omicron wanes in 2022, there are possibilities for new strains or that the disease becomes endemic. In either scenario, Moderna is poised to benefit from any future administrations of its vaccine.As of the time of this writing, Moderna has fallen over 50% from its 52-week in August 2021, equating to more than $98 billion of market capitalization being erased. At roughly nine times its trailing-12-month sales and a healthy profitability and cash profile, Moderna looks like a good buy going into 2022.","news_type":1},"isVote":1,"tweetType":1,"viewCount":545,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}